Connect with us

General Other

A Florida man walking his dog was attacked by an alligator. He used 2 fingers to escape

mm

Published

on

A Florida man walking his dog was attacked by an alligator. He used 2 fingers to escape

Mark Johnson is lucky to tell the tale.

The 61-year-old Florida artist was viciously attacked by an alligator behind his Port St. Lucie home over the weekend, TC Palm first reported.

Johnson said he was out walking his dog Rex by a canal near his house around 9:30 a.m. Sept. 13 when he noticed an alligator at the water’s edge. Then the gator noticed them, and lunged.

Johnson yelled for Rex, a golden retriever, to get on home, and he obeyed.

As for the man, his shoe — a Croc sandal — got stuck in the mud and the gator grabbed a hold of his leg. Johnson wrestled with the gator on the ground, and was able to poke it in the eye with two index fingers. That’s when it released its ferocious grip and swam away.

“I’m still in disbelief that the gator lunged at me like he did,” the bite victim told the Miami Herald Wednesday. “I’m a native Floridian, been around these things my whole life, and this would have been the last thing I would ever expected.”

Johnson says poking the large reptile in the eye was the only option, and he’s thankful it worked.

“He was in the stage where he was about to go his [death] roll, that would have made the situation a lot worse,” the Winter Garden native said of the spinning maneuver to subdue prey. “It’s a story most folks should know about, especially in South Florida.”

Johnson, who estimated the beast to be around nine feet long, received about 60 stitches in his leg plus another five in the index finger on his left hand.

He contacted the Florida Fish and Wildlife Conservation Commission, but a nuisance trapper was unable to locate the alligator, Johnson told the Miami Herald.

“A contracted nuisance alligator trapper was dispatched to the location,” the FWC confirmed to the Herald, adding the incident is being investigated.

Outdoors photographer Ed Killer posted a picture of the man and his injuries on Facebook, saying that Johnson “survived a near miss.”

To report a nuisance alligator, call FWC’s Nuisance Alligator Hotline at 866-392-4286.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

General Other

Sri Lanka government decides to ban cattle slaughter

mm

Published

on

Sri Lanka government decides to ban cattle slaughter

COLOMBO, Sri Lanka (AP) — Sri Lanka’s government announced Tuesday that it will ban cattle slaughter, saying it would help the dairy industry and thereby save money used to purchase imported milk powder.

But an analyst said the decision was politically motivated to please the Buddhist majority and would harm dairy farmers.

Cabinet ministers decided at a meeting Monday to immediately amend the Animal Act, the Cattle Slaughter Ordinance and other laws and regulations passed by local authorities regarding cattle slaughter, the government’s information department said.

It said the Cabinet believed that an increase in cattle slaughter was making it hard for traditional farmers to acquire cows for dairy farming.

Independent political analyst Kusal Perera called the decision “totally counter-productive” because “no milk industry can sustain itself without a beef industry.”

He said the move is “more a political decision than an economic one” to please the majority Sinhala Buddhist constituency.

Buddhists as well as minority Hindus avoid beef for religious and cultural reasons. Some Buddhist monks and allied groups have long sought a ban on cattle slaughter.

Perera said dairy farming in Sri Lanka is mostly a cottage industry in which individual farmers also raise cattle for side income. Such farmers will have difficulty if they are denied the opportunity to slaughter and sell unproductive, aging cattle.

The Cabinet said it will implement a suitable program for aging cattle that can no longer be used effectively for agricultural purposes, but didn’t describe the program.

It also said the government will import beef and provide it at a concessionary price to people who consume it since it will not be produced domestically.

According to government statistics, domestic milk production accounts for 45% of total demand, resulting in imports of $270 million of milk powder in 2018. The country produced over 29,000 tons of beef in 2019, up 1,000 tons from 2018.

Perera said the slaughter ban will particularly target Muslim traders who have a monopoly on the beef trade, “but they will shift to other businesses such as poultry and mutton.”

Buddhists account for more than 70% of the country’s 20 million people. Ethnic minority Tamils, who are mainly Hindus, comprise about 15% of the population, while 9% are Muslims.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

General Other

The Bose Solo 5 soundbar offers ‘remarkable’ audio—and it’s on sale

mm

Published

on

The Bose Solo 5 soundbar offers 'remarkable' audio—and it’s on sale

Yahoo Life is committed to finding you the best products at the best prices. We may receive a share from purchases made via links on this page. Pricing and availability are subject to change.

Bose Solo 5 Television Sound System is on sale for $199. (Photo: Bose)

If you love watching movies but loathe your TV’s less-than-stellar sound quality, we found a deal that will be music to your ears. Right now, the Bose Solo 5 Television Sound System—a small, but powerful wireless soundbar engineered to enhance on-screen dialogue—is on sale for just $199, or $50 off at Amazon.

Satisfied Amazon shoppers are coming out in droves to praise the Bose Solo 5 soundbar for transforming their home theater experiences. In fact, it’s so popular that it has earned a flawless five-star rating from an impressive 6,400 reviewers. “The improvement in sound from the TV speakers is remarkable—definitely Bose quality in a small package,” one fan wrote.

So what makes this slim, all-in-one sound system so dynamic? First of all, it’s by Bose—a household name synonymous with quality, longevity, and timeless design. The brand was founded by an MIT professor of electrical engineering on a quest for better sound—and its state-of-the-art technology is now utilized in places like the Sistine Chapel and the Japan National Theater.

Bose is also the brand of choice in countless homes just like yours. It not only beats your TV’s built-in speakers by a long shot, but it’s a cord-free, space-saving alternative to a multi-component sound system. The slim unit sits inconspicuously under your TV or on a media stand while broadcasting your favorite shows, films and podcasts in crystal clear detail—thanks to its unique, bass-enhancing dialogue mode.

This slim device blend seamlessly and deliver major sound. (Photo: Bose)
This slim device blend seamlessly and deliver major sound. (Photo: Bose)

“If you’re looking for great sound and you don’t need something to shake the walls, this is what you want. I’ve tried it with movies, tv shows, ball games,” as a proud shopper explained. “The sound is clear and you hear everything you should. I’m hearing dialogue in the background of movies I’ve seen countless times that I had never heard before. You’ll never go back to tv speakers again.”

This Bose powerhouse soundbar is a no-brainer for music lovers, too. One reviewer reported, “I also use this as a speaker to play music during house parties. It is easily loud enough for any type of music. This is my new go-to for playing music around the house or out on the patio.”

The Bose Solo 5 TV Sound System is a breeze to set up and use, too—even for tech novices. Save 20 percent by ordering the Bose Solo 5 TV Sound System today, then prepare to be blown away.

The reviews quoted above reflect the most recent versions at the time of publication.

Read More from Yahoo Life:

Follow us on Instagram, Facebook, Twitter and Pinterest for nonstop inspiration delivered fresh to your feed, every day.

Want daily pop culture news delivered to your inbox? Sign up here for Yahoo Entertainment & Life’s newsletter.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

General Other

Here’s what happens to the stock market after the first presidential debate in an election year

mm

Published

on

Here's what happens to the stock market after the first presidential debate in an election year

TipRanks

Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100%

When it comes to the market’s wild swings, is the glass half empty or half full? Oppenheimer’s chief investment strategist John Stoltzfus is taking the latter view.Despite the volatility that has ruled the market over the last few weeks, Stoltzfus actually likes what he’s witnessing in both the market and the economy. In particular, he points to U.S. companies that have been outperforming most other markets around the world as exciting plays, with the innovation in the U.S. reflecting a key component of his bullish thesis.“The U.S. is outperforming most of the markets around the world — whether it’s developed markets or emerging markets… We’ve taken out the froth that had come into the market in certain [mega cap] names. It may be a good opportunity to pick up some really good, high quality growth stories that are on sale right now,” Stoltzfus noted.Additionally, the strategist believes the S&P 500 could climb back to its September 2 high point, based on improving economic data. The approval of a COVID-19 vaccine as well as an election outcome that is “friendly to the domestic economy, business, job growth and the taxpayer” could also push the index higher.Turning Stoltzfus’ outlook into tangible recommendations, Oppenheimer analysts are pounding the table on two stocks, with these pros seeing over 100% upside potential in store. Running the tickers through TipRanks’ database, we wanted to find out exactly what makes them so compelling.Brickell Biotech (BBI)Focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases, Brickell Biotech wants to improve the lives of patients everywhere. Given the potential of the company’s lead candidate and its $0.82 share price, Oppenheimer thinks that now is the time to pull the trigger.Sofpironium bromide (SB), a prescription treatment for axillary hyperhidrosis (AH, or excessive underarm sweating), is entering U.S. Phase 3 trials. This program will consist of two identical six-week studies, and will evaluate its ability to improve the condition per the objective (gravimetric sweat production) and subjective (HDSM-Ax) co-primary endpoints. Each is expected to last 12 months, and the first will kick off next quarter.Roughly 10 million people in the U.S. suffer from AH, with this condition interfering with daily social and professional activities. Currently, only 2.3 million receive prescription treatment, and some resort to invasive or permanent interventions like Botox, MiraDry or surgery.Oppenheimer’s Leland Gershell argues that more conservative approaches could be used to meet these medical needs. He also believes the recent entry of Eli Lilly’s competing product, Qbrexza, represents a significant step forward. That said, there’s “room for improvement” with this anti-cholinergic approach.Looking at a U.S. Phase 2b trial, the highest dose of BBI’s SB gel (15%) demonstrated 46% greater sweat reduction per gravimetric analysis compared to the placebo, with significant reductions in a validated patient-reported outcome instrument seen at all doses. Based on the trial data, efficacy is over 50% better than Qbrexza per label, despite higher baseline severity. In addition, their safety profiles were relatively similar.It should be noted that BBI will market the drug to U.S. dermatologists through a specialty salesforce of 120 representatives. According to Gershell’s estimates, uptake by 110,000 patients per year (just 5% of the currently treated AH population) translates to $200 million in gross sales. The analyst adds that patent issuance could extend market exclusivity to 2040.Adding to the good news, on September 25, BBI announced that Kaken Pharmaceutical, its development partner, got the green light to manufacture SB in Japan for the treatment of AH. Japan is the first country to approve the candidate, with the launch expected later this year.To sum it all up, Gershell stated, “By virtue of its efficacy, tolerability, and antiperspirant-like application, we believe SB offers an attractive profile in a market that offers much room for improved solutions. We encourage risk-tolerant investors to build a position ahead of upcoming newsflow.”To this end, Gershell rates BBI an Outperform (i.e. Buy) along with a $5 price target. This target conveys the analyst’s confidence in BBI’s ability to surge 502% from current levels. (To watch Gershell’s track record, click here)Looking at the consensus breakdown, 2 Buys and no Holds or Sells have been published in the last three months. As a result, BBI gets a Moderate Buy consensus rating. The $5 average price target is identical to Gershell’s. (See BBI stock analysis on TipRanks)Aldeyra Therapeutics (ALDX)As for Oppenheimer’s other pick, Aldeyra Therapeutics works to bring new treatment options for immune-related diseases to market. Based on the solid progress of its pipeline, the firm has high hopes for this healthcare name.Representing Oppenheimer, analyst Justin Kim points out that he came away from a recent conversation with the CEO even more confident in ALDX’s long-term growth prospects. Pivotal studies on reactive aldehyde species (RASP) are slated for Q4 2020, evaluating the action of reproxalap, Aldeyra’s lead therapy designed to clamp down on overactive inflammation, on tear levels of RASP over a period ranging from 1-2 days to 28 days. “Based on Phase 2a results, we are confident in the ability to replicate results in Q4 2020,” Kim stated.Given the potential of dry eye disease (DED) in the near-term, the analyst expects significant investor focus to land on clinical trial execution (Phase 3 RASP studies and safety study), which would support a potential NDA filing by the end of 2021, in Kim’s opinion. “Despite some volatility in the shares, we see a solid setup emerging as the company initiates its Phase 3 RASP studies in dry eye disease (DED),” he said.Speaking to the potential of RASP as an accepted dry eye endpoint, ALDX has experienced “a watershed moment,” with it facilitating an expedited path to registration (from traditional sign endpoints) and greater likelihood of clinical trial success, based on reproxalap’s mechanism of action (MoA) as a RASP-trap, according to Kim.He added, “Moreover, agreement on RASP could have broader implications for a commercial launch in dry eye, a market that we believe will see segmentation as more therapies with targeted MoAs become incorporated into the armamentarium.”“We continue to be impressed by the progress in achieving a potential concurrent filing for dry eye and allergic conjunctivitis (AC), appreciating the importance of a differentiated dry eye agent with action also in AC. As the dry eye therapeutic landscape increases its options, we expect greater segmentation of the heterogeneous patient population potentially beginning with reproxalap’s positioning in ‘allergic dry eye’,” the analyst concluded. For the rest of 2020, focus is likely to stay on Phase 3 study designs (assay work/development), execution and the potential readout in DED, which could set the stage for a commercial launch in DED and AC in 2022.If that wasn’t enough, based on the broader pipeline of candidates targeting PVR, inflammatory conditions and COVID-19, Kim sees “a rich environment of catalysts for the shares over the coming 12-18 months.”It should come as no surprise, then, that Kim stayed with the bulls. To this end, he kept an Outperform rating and $15 price target on the stock. Investors could be pocketing a gain of 110%, should this target be met in the twelve months ahead. (To watch Kim’s track record, click here)What does the rest of the Street have to say? Only Buy ratings, 2 to be exact, have been issued in the last three months. So, the consensus rating is a Moderate Buy. In addition, the $23.50 average price target suggests 227% upside potential from current levels. (See ALDX stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

Trending